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Both varicella (chickenpox), and the reactivated form of herpes zoster (shingles), may cause 
neurological complications with various central nervous system (CNS) manifestations.  Following 
introduction of PCR as a diagnostic method, the possibilities to detect the virus in cerebrospinal fluid 
(CSF) and to explore this disease, have dramatically improved. 
With the quantifiable properties of real-time PCR the question arose whether VZV viral load was 
correlated to the severity of neurological disease. In 97 patients, the medical records were 
retrospectively studied and the spectrum of clinical entities discerned. CSF VZV DNA was quantified 
in 66 of these cases. Baseline viral loads were higher in patients with meningitis and encephalitis as 
compared with those suffering from Ramsay Hunt syndrome. However, these differences did not 
reflect the severity of disease why this parameter was not a reliable predictor of outcome. 
Additionally, based on our data, VZV seems to be a more common aetiological agent of CNS 
infections than previously thought. 
Despite the usefulness of PCR, this technique has its diagnostic limitations. In patients with late 
diagnosis, the VZV DNA may be absent at time of PCR analysis. Serological analysis for detection of 
intrathecal antibody production is then required. Using a crude VZV antigen does not properly 
discriminate between antibodies to VZV and HSV-1. We produced and evaluated a purified 
glycoprotein antigen, VZVgE. When 854 serum samples were analysed, VZVgE-ag showed equal 
sensitivity and at least as high specificity compared with VZVwhole-ag.  
VZVgE was also evaluated as a serological antigen in CSF. Paired samples of CSF and serum from 29 
patients with clinical diagnosis of VZV CNS infection (n=15) or herpes simplex encephalitis (HSE) 
(n=14), all confirmed by PCR were analysed. In ELISA, 11/14 HSE patients showed intrathecal 
antibody production with VZVwhole-ag compared with 4/14 using VZVgE-ag. In the patients with 
VZV CNS infection, the two antigens showed comparable results. When the CSF/serum samples pairs 
were diluted to identical IgG concentrations, higher CSF/serum optical density (OD) ratios were found 
in VZV patients using VZVgE-ag compared with VZVwhole-ag. These results show that VZVgE is a 
sensitive antigen for serological diagnosis of VZV CNS infection without cross-reactivity to HSV-1 
IgG. 
To evaluate the potential degree of brain damage in patients with VZV CNS infections, we 
prospectively studied the CSF concentrations of neuron-specific light chain neurofilament protein 
(NFL), glial fibrillary acidic protein (GFAp) and S-100β protein in 24 patients with VZV DNA 
positivity and acute neurological symptoms. Concentrations of CSF NFL and GFAp were moderately 
increased, while the S-100β levels were reduced. These results indicate that VZV might induce 
neuronal damage and astrogliosis, and this finding was most pronounced in the patients with VZV 
encephalitis. 
The cognitive impairment in patients with VZV CNS infections is largely unknown. We investigated 
the cognitive impairment in 14 patients with predominant CNS infections caused by VZV in a 3-year 
follow-up. The VZV patients performed worse than controls (n=28) on 4 tests covering the domains of 
speed and attention, memory and learning and executive function. The VZV patients were also 
classified into the concept of mild cognitive impairment (MCI), which is associated with development 
of dementia. A greater proportion of VZV patients was classified with MCI compared with controls. 
These findings suggest that patients with previous VZV CNS infection might carry a risk of long-term 
cognitive impairment. 
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